Aequus Pharmaceuticals

Driving better health outcomes for Canadians

A specialty pharma company focused on bringing healthcare solutions to Canadians through licensing and partnerships
AQS TSX-V
$0.000
$0.00
0.00%
(in CAD) Data as of today
Minimum 20 minute delay
AQSZF OTCQB
$0.000
$0.00
0.00%
(in USD) Data as of today
Minimum 20 minute delay

Your Pharma Partner
In
Canada


Based in Canada, Aequus has end-to-end capabilities with experience navigating the full commercialization cycle

Opportunistic in our approach, we build our portfolio through partnerships

We work with Health Care Providers to guide our mission to address unmet needs of Canadians

Our Team is Ready to Collaborate with You

Distribution

Are you interested in launching your product in the Canadian Market?

Sales & Marketing

Leverage our experienced in-house sales team and commercial infrastructure to grow your product

Partnering

We strive for excellence in our collaborations to support the growth of your global footprint

Reach out to our Business Development team to discuss your Canadian journey

busdev@aequuspharma.ca

We help partners succeed in the Canadian market

Aequus is seeking new long-term partnerships with companies looking to bring, launch and grow their differentiated product to Canada

Aligning our objectives to our partners goals and helping you realize your full potential in the Canadian market

Download
Corporate Deck

About Aequus

We are a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas.

We continue to build our pipeline with new partnerships and have recently added a number of commercial stage products through in-licensing and distribution agreements.

Our commercial programs are supported and guided by insights from patients, physicians, and payers. Aequus’ management team has a proven track record of successfully managing the required clinical development, regulatory approval processes, and marketing of products. We continue to leverage our internal capabilities and know-how to execute an efficient commercial strategy and development plan to drive shareholder value.
Aequus logo

News Releases

Products + Pipeline + Collaborations

Marketed
Pipeline
Collaboration

PAUL® Glaucoma Implant

Glaucoma | Pipeline

Pre-Registration

Pre-Registration

Pre-Registration

Pre-Registration

Pre-Registration

Already available in over 40 countries around the world, PAUL® is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL® has introduced many innovative design features and unified these into one device and offers an innovative solution for patients with moderate to severe glaucoma.

Download Monograph
Status

ZIMED® PF

Glaucoma | Marketed

Launched

Launched

Launched

Launched

Launched

Preservative-free Bimatoprost 0.03%, ophthalmic solution.
Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. ZIMED™ PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The anticipated timing for approval is December 2022.

Download Monograph
Status
Approved

REV-0100 / ReVision

Stargardt Disease | Collaboration

Pre-Clinical

Pre-Clinical

Pre-Clinical

Pre-Clinical

Pre-Clinical

REV-0100 is in preclinical development as a treatment for Stargardt disease. It was awarded both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

Aequus has entered into a partnership with ReVision on the development program and holds the exclusive right to negotiate North American commercial rights.

Download Monograph
Status
Pre-Clinical

Our Leadership Team

Doug Janzen

Doug Janzen

Chairman & Chief Executive Officer

Has been involved in the Life Sciences industry for the past 19 years.

Currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies.

President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck.

Investment banker with Cormark Securities, acting as Managing Director of Life Sciences.

Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards.

Past winner of Business in Vancouver’s Top 40 Under 40 Award.

Ann Fehr

Ann Fehr

Chief Financial Officer & Corporate Secretary

Principal at Fehr & Associates.

Ms. Fehr assists Aequus with financial and regulatory reporting. She has been professional accountant since 1996 and has been a consultant at Fehr & Associates since 2010.

Ms. Fehr has years of experience in senior management and consulting and has served as CFO for a number of public companies since 20009.

She has also led companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution.

Grant Larsen

Grant Larsen

Chief Commercial Officer

Joined the Aequus team in August of 2020 in the role of Chief Commercial Officer.  

Close to 20 years of senior management positions in North American eye care industry.

In-depth knowledge of Canadian Optometry, direct to consumer marketing, online technology, and medical devices, brings important experience to accelerate growth for Aequus’ expanding portfolio of products.

Past CEO of Eye Recommend, one of Canada’s largest cooperatives of optometrists.

Held senior leadership positions at Allergan, Nikon Optical Canada, and Digital ECP.

Anne Stevens

Anne Stevens

Director

Over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry.

Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies.

Part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development.

Served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D.

5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.

Chris Clark

Chris Clark

Director

Over 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector.

Financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems.

Chief Financial Officer at Neovasc Inc. and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company.

Received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998.

Honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.

Marc Lustig

Marc Lustig

Director

Marc Lustig joined the Aequus team in February of 2021 as a Director.  Marc Lustig holds MSc and MBA degrees from McGill University.

He began his professional career in the pharmaceutical industry at Merck & Co. In 2000, he started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities. For the next 14 years, Mr. Lustig worked at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming a Principal at KES7 Capital.

In 2015 Mr. Lustig founded CannaRoyalty Corp. (Origin House). Origin House was sold to Cresco Labs in January 2020.  Mr. Lustig is currently a Director of Cresco Labs and Pharmacielo Ltd. He is also Chairman of both Trichome Financial Corp. and IMC Cannabis.

Annual General Meeting Materials

The Annual General Meeting of shareholders of Aequus Pharmaceuticals Inc. will be held at the offices of Blake, Cassels, & Graydon LLP.

Address: 1133 Melville Street, Suite 3500, Vancouver, British Columbia, V6E 4E5
Date: July 25th, 2023
Time: 10:00am (PDT)

Financial Statements & Other Reports

Contact Us

Our Location

Send us a message